GSK's Arexvy gets EU nod for 50-59 RSV prevention
Ticker: GLAXF · Form: 6-K · Filed: Jul 29, 2024 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Jul 29, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: regulatory-approval, vaccine, pharmaceuticals
Related Tickers: GSK
TL;DR
GSK's RSV vaccine Arexvy just got a green light from EU regulators for adults 50-59 at risk. Big market expansion incoming.
AI Summary
GSK plc announced on July 29, 2024, that its Arexvy vaccine for Respiratory Syncytial Virus (RSV) received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP). This recommendation is for the prevention of RSV in adults aged 50-59 who are at increased risk of the disease.
Why It Matters
This positive opinion expands the potential market for GSK's RSV vaccine in Europe, potentially increasing revenue and market share in the preventative health sector.
Risk Assessment
Risk Level: low — This is a positive regulatory announcement for an existing product, not a significant financial event or new risk.
Key Players & Entities
- GSK plc (company) — Registrant and developer of Arexvy
- Arexvy (product) — RSV vaccine
- European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) (company) — Regulatory body that issued the positive opinion
- July 29, 2024 (date) — Date of announcement
FAQ
What is the specific indication for which Arexvy received a positive CHMP opinion?
Arexvy received a positive CHMP opinion for the prevention of Respiratory Syncytial Virus (RSV) in adults aged 50-59 who are at increased risk of the disease.
When was this positive opinion announced?
The positive opinion was announced on July 29, 2024.
What is the name of GSK's RSV vaccine?
GSK's RSV vaccine is named Arexvy.
Which regulatory body issued the positive opinion for Arexvy?
The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued the positive opinion.
What is the age group targeted by this new positive opinion for Arexvy?
The positive opinion is for adults aged 50-59.
Filing Stats: 1,325 words · 5 min read · ~4 pages · Grade level 13.4 · Accepted 2024-07-29 06:16:02
Filing Documents
- a1391y.htm (6-K) — 49KB
- 0001654954-24-009501.txt ( ) — 51KB
SIGNATURES
SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.   GSK plc   (Registrant)     Date: July 29, 2024         By:/s/ VICTORIA WHYTE --------------------------       Victoria Whyte   Authorised Signatory for and on   behalf of GSK plc